- Home
- PDSB vs IGC Comparison
PDSB vs IGC Comparison
Compare PDSB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- IGC
- Stock Information
- Founded
- PDSB 2005
- IGC 2005
- Country
- PDSB United States
- IGC United States
- Employees
- PDSB N/A
- IGC N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- IGC Health Care
- Exchange
- PDSB Nasdaq
- IGC Nasdaq
- Market Cap
- PDSB 44.5M
- IGC 39.8M
- IPO Year
- PDSB N/A
- IGC N/A
- Fundamental
- Price
- PDSB $0.94
- IGC $0.42
- Analyst Decision
- PDSB Strong Buy
- IGC Strong Buy
- Analyst Count
- PDSB 2
- IGC 2
- Target Price
- PDSB $10.00
- IGC $4.00
- AVG Volume (30 Days)
- PDSB 489.6K
- IGC 875.3K
- Earning Date
- PDSB 11-13-2025
- IGC 11-11-2025
- Dividend Yield
- PDSB N/A
- IGC N/A
- EPS Growth
- PDSB N/A
- IGC N/A
- EPS
- PDSB N/A
- IGC N/A
- Revenue
- PDSB N/A
- IGC $1,327,000.00
- Revenue This Year
- PDSB N/A
- IGC $3.54
- Revenue Next Year
- PDSB N/A
- IGC $15.12
- P/E Ratio
- PDSB N/A
- IGC N/A
- Revenue Growth
- PDSB N/A
- IGC 24.95
- 52 Week Low
- PDSB $0.85
- IGC $0.25
- 52 Week High
- PDSB $3.48
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- PDSB 40.57
- IGC 56.07
- Support Level
- PDSB $0.89
- IGC $0.36
- Resistance Level
- PDSB $1.03
- IGC $0.43
- Average True Range (ATR)
- PDSB 0.06
- IGC 0.02
- MACD
- PDSB 0.00
- IGC -0.00
- Stochastic Oscillator
- PDSB 31.67
- IGC 77.30
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.